{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-005042","form_type":"8-K","ticker":"COSM","cik":"0001474167","company_name":"Cosmos Health Inc.","filed_at":"2023-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.026297+00:00","generated_at":"2026-06-13T11:40:28.469860+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cosmos Health completes Cana buy for $1.67M; assets valued over $10M, expects gain","bullets":["Purchase price $1.67M (€800k cash + $800k stock at $17.25/share) for 100% of Cana; closed June 30, 2023.","Cana's tangible and intangible assets independently valued >$10M; Cosmos expects substantial gain on bargain purchase.","Cana's 54,000 sq ft production facility added; prior acquisitions: Bikas GP (>$10M annual revenue) and ZipDoctor.","Binding LOI for German-based Docpharm; projected to add $30M annual revenue by 2025.","R&D clinical trials for obesity/weight management scheduled to start Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-005042","json":"https://secwatch.observer/filing/0001477932-23-005042.json","markdown":"https://secwatch.observer/filing/0001477932-23-005042.md","text":"https://secwatch.observer/filing/0001477932-23-005042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223005042/0001477932-23-005042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223005042/cosm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T11:40:28.469860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8af650e064e337116d64b92a0f1cfdf7c264816b","claim":"Cosmos Health Inc. completed an acquisition involving Pharmaceutical Laboratories CANA, S.A. for approximately $1.67 million (closed 2023-06-30).","evidence_excerpt":"On June 30, 2023, Cosmos Health Inc. (the “Company”) completed the acquisition of one hundred (100%) percent of the equity of Pharmaceutical Laboratories CANA, S.A. (“Cana Holdings”). The Purchase Price for the shares was approximately $1.67 million consisting of €800,000 in cash and $800,000 in stock, based on an issuance price of $17.25 per share.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223005042/0001477932-23-005042-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Pharmaceutical Laboratories CANA, S.A."},{"label":"Consideration","value":"approximately $1.67 million"},{"label":"Closing","value":"2023-06-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}